SAN FRANCISCO — Among patients with symptomatic, severe native aortic regurgitation at high surgical risk, the JenaValve Trilogy transcatheter heart valve system (JenaValve Technology) met its primary ...

WASHINGTON — A phase 3 randomized trial will soon begin for the first transcatheter aortic valve replacement (TAVR) device for the treatment of aortic valve regurgitation after promising results in a ...

Aortic regurgitation occurs when blood leaks back into the left ventricle due to a leaky aortic valve. This is a type of valve disease in the heart. Aortic regurgitation can lead to some heart damage ...

Depending on the severity of the condition, doctors decide whether it can be treated with medication, repair or replacement. Aortic stenosis is one of the most common heart valve diseases, affecting ...

The US Food and Drugs Administration (FDA) is expected to approve the JenaValve Trilogy System, a transcatheter aortic valve replacement (TAVR) device designed for aortic regurgitation (AR), by late ...

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, outcomes were similar among patients who had undergone transcatheter aortic-valve ...

A new study found that older patients with atrial functional mitral regurgitation who underwent mitral valve surgery had significantly better outcomes than those who received medical management alone, ...

Among young adults with aortic regurgitation (AR), those undergoing aortic valve replacement (AVR) before they met standard criteria were more likely to achieve good results from the surgery, a study ...